Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer

膀胱癌患者中 [(68)Ga]-FAPI 和 [(18)F]-FDG PET/CT 的直接个体内比较

阅读:1

Abstract

AIM/PURPOSE: Fibroblast activation protein-(FAP)-ligands, a novel class of tracers for PET/CT imaging, demonstrated promising results in previous studies in various malignancies compared to standard [(18)F]FDG PET/CT. (68)Ga-labeled fibroblast activation protein inhibitor-([(68)Ga]Ga-DOTA-FAPI)-PET/CT impresses with sharp contrasts in terms of high tumor uptake and low background noise leading to clear delineation. [(18)F]FDG PET/CT has limited accuracy in bladder cancer due to high background signal. Therefore, we sought to evaluate the diagnostic potential of [(68)Ga]FAPI in patients with bladder cancer. MATERIAL AND METHODS: This retrospective analysis consisted of 8 patients (median age 66), 7 of whom underwent both [(68)Ga]FAPI and [(18)F]FDG PET/CT scans with a median time interval of 5 days (range 1-20 days). Quantification of tracer uptake was determined with SUV(max) and SUV(mean). Furthermore, the tumor-to-background ratio (TBR) was derived by dividing the SUV(max) of tumor lesions by the SUV(max) of adipose tissue, skeletal muscle, and blood pool. RESULTS: Overall, 31 metastases were detected in five patients including lymph node metastases (n = 23), bone metastases (n = 4), lung metastases (n = 3), and a peritoneal metastasis (n = 1). In one patient, [(68)Ga]FAPI demonstrated significant uptake in the primary tumor located in the bladder wall. [(68)Ga]FAPI-PET/CT demonstrated significantly higher uptake compared to [(18)F]FDG PET/CT with higher mean SUV(max) (8.2 vs. 4.6; p = 0.01). Furthermore, [(68)Ga]FAPI detected additional 30% (n = 9) lesions, missed by [(18)F]FDG. TBR demonstrated favorable uptake for [(68)Ga]FAPI in comparison to [(18)F]FDG. Significant differences were determined with regard to metastasis/blood pool ([(68)Ga]FAPI 5.3 vs [(18)F]FDG 1.9; p = 0.001). CONCLUSION: [(68)Ga]FAPI-PET/CT is a promising diagnostic radioligand for patients with bladder cancer. This first described analysis of FAP-ligand in bladder cancer revealed superiority over [(18)F]FDG in a small patient cohort. Thus, this so far assumed potential has to be confirmed and extended by larger and prospective studies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。